0001209191-20-031876.txt : 20200522 0001209191-20-031876.hdr.sgml : 20200522 20200522193126 ACCESSION NUMBER: 0001209191-20-031876 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200521 FILED AS OF DATE: 20200522 DATE AS OF CHANGE: 20200522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Munshi Amit CENTRAL INDEX KEY: 0001612551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 20907633 MAIL ADDRESS: STREET 1: C/O EPIRUS BIOPHARMACEUTICALS, INC. STREET 2: 699 BOYLSTON STREET, 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-21 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001612551 Munshi Amit C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 1 1 0 0 President and CEO Common Stock 2020-05-21 4 M 0 50000 14.60 A 57750 D Common Stock 2020-05-21 4 S 0 50000 55.00 D 7750 D Common Stock 2020-05-22 4 M 0 34800 14.60 A 42550 D Common Stock 2020-05-22 4 S 0 5390 56.6731 D 37160 D Common Stock 2020-05-22 4 S 0 9017 57.5205 D 28143 D Common Stock 2020-05-22 4 S 0 13931 58.6075 D 14212 D Common Stock 2020-05-22 4 S 0 6462 59.1174 D 7750 D Employee Stock Option (right to buy) 14.60 2020-05-21 4 M 0 50000 0.00 D 2024-02-13 Common Stock 50000 149800 D Employee Stock Option (right to buy) 14.60 2020-05-22 4 M 0 34800 0.00 D 2024-02-13 Common Stock 34800 115000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.19 to $56.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, and 5 to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.07 to $57.97, inclusive. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.22, inclusive. The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2020-05-22